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Summary
Background: Chemotherapy remains the primary mode of treatment for metastatic carcinoma of the esophagus.
The efficacy of various chemotherapeutic regimens has been studied predominantly in patients with squamous cell
carcinoma of the esophagus. In light of the increasing incidence of adenocarcinoma of the esophagus, studies eval-
uating newer chemotherapy agents, such as docetaxel, in this patient population are necessary. The objective of this
trial was to determine the complete and partial response rate of docetaxel in patients with incurable adenocarcinoma
of the esophagus.
Patients and methods: Eligible patients had histologically confirmed metastatic adenocarcinoma of the eso-
phagus or locally extensive disease not curable with surgery or radiation therapy. Patients were either chemotherapy
naive or previously treated with chemotherapy (including paclitaxel). Docetaxel was administered at a dose of
75 mg/m2 every three weeks intravenously. Appropriate imaging studies/examinations were obtained after every
two cycles to evaluate response.
Results: A total of 22 patients were enrolled in the trial. Chemotherapy-naive patients achieved a response rate
of 18% (95% CI = 2.3 to 51.8) while patients who received prior chemotherapy achieved a 0% response rate (95%
CI = 0 to 25). There were no complete responses. The overall median survival time is 3.4 months and the one-year
survival rate is 21%. The toxicities included febrile neutropenia (32%) as well as grade 3 and 4 fatigue (14%) and
anorexia (9%).
Conclusions: Although chemotherapy naive patients achieved an 18% response rate and no responses were seen
in previously treated patients, the limitations of this trial does not allow for any definitive conclusions to be made
about the efficacy of single agent docetaxel chemotherapy in patients with incurable esophageal cancer.
Introduction
The incidence of adenocarcinoma of the esophagus is
rising [1]. Unfortunately, those diagnosed with recur-
rent or metastatic disease are not curable. Chemothera-
peutic agents play a major role in palliative therapy
and remain the primary mode of treatment. Most
of the chemotherapeutic agents, such as cisplatin,
5-fluorouracil, bleomycin, and etoposide have been
evaluated previously in patients with squamous cell
carcinoma of the esophagus [2–4]. The majority of
the trials performed were in small numbers of patients
with reported response rates from 15 to 40%. The re-
sponse was usually of short duration and there was no
survival benefit apparent with single agent chemother-
apy. Combination chemotherapy has been evaluated
with slightly improved results in terms of longer dur-
ation of response (3 to 6 months), but there was still
little improvement in the dismal overall survival rate.
In light of the rising incidence of adenocarcinoma of
the esophagus, studies evaluating newer chemotherapy
agents, such as docetaxel, in this patient population are
necessary.
Docetaxel is a cytotoxic antineoplastic agent which
disrupts the microtubular network essential for mi-
totic and interphase cellular functions [5]. This semi-
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synthetic compound is derived from the needles of
the European yew tree, Taxus baccata. Docetaxel is
a structurally similar compound to paclitaxel, but has
a different activity profile. For example, docetaxel
affects mitotic structures at the centrosome while pac-
litaxel affects them at the mitotic spindle. Docetaxel
acts primarily during the S phase of the cell cycle
versus the G2/M phase. In the P388 leukemia cell line,
docetaxel has been shown to have three-fold higher in-
tracellular concentration compared to paclitaxel and at
least three times slower efflux compared to paclitaxel
[6]. These differences may contribute to the higher
in vitro anti-tumor activity observed with docetaxel
compared to paclitaxel in multiple murine and human
tumor cell lines, such as in gastric cancer cell lines [7].
Paclitaxel has been studied in patients with ad-
enocarcinoma and squamous cell carcinoma of the
esophagus. Ajani et al. reported a 34% and 28%
response rate in paclitaxel treated patients with ad-
enocarcinoma and squamous cell carcinoma of the
esophagus, respectively [8]. These previously un-
treated patients who had excellent performance status
experienced tolerable side effects with paclitaxel. One
conclusion of the trial was that paclitaxel is an act-
ive agent against both types of esophageal cancer in
previously untreated patients.
Docetaxel has been evaluated in a phase II trial
of previously untreated patients with adenocarcinoma
of the upper gastrointestinal tract [9]. At a dose of
100 mg/m2 given every 3 weeks, an objective response
rate of 17% was reported. Although this response
rate was lower than anticipated, the majority of pa-
tients (76%) in the trial had gastric cancer, a disease
also with minimal response to paclitaxel. Therefore,
it is reasonable to expect a higher response rate with
docetaxel in esophageal cancer patients.
The primary objective of this trial was to determ-
ine the complete and partial response rate of docetaxel
in patients with incurable adenocarcinoma of the eso-
phagus. Secondary objectives included evaluating sur-




Patients with histologically confirmed adenocar-
cinoma of the esophagus, cardia or gastroesophageal
junction were enrolled at three sites: the Johns Hop-
kins Oncology Center, the University of Michigan and
the Georgetown University Hospital. Eligible patients
with metastatic disease or locally extensive disease not
curable with surgery or radiation therapy were either
chemotherapy naive or previously treated with chemo-
therapy (including paclitaxel). Patients were greater
than 18 years of age with an ECOG performance status
≤ 2.
Adequate bone marrow and hepatic function was
necessary and was defined as having absolute neut-
rophil count (ANC) ≥ 1000, platelets ≥ 100,000,
total bilirubin < upper limit of normal (ULN), SGOT
and/or SGPT ≤ 2.5 × ULN if alkaline phosphatase
is ≤ ULN, or alkaline phosphatase may be up to 4
× ULN if transaminases are ≤ ULN. Patients were
not allowed to have any CNS metastasis, pre-existing
peripheral neuropathy ≥ grade 2 and must have a life
expectancy of ≥ 12 weeks.
Pre-treatment evaluation included signed written
informed consent, complete history and physical ex-
amination, laboratory tests, CT scans of the chest,
abdomen, and pelvis, EKG and urine or serum bHCG
if the patient was a female of child bearing age. The
study was approved by the committees for human
research at all three clinical centers.
Treatment plan
Docetaxel was administered at a dose of 75 mg/m2
every 3 weeks intravenously in the outpatient onco-
logy clinic. One treatment every three weeks was
considered one cycle. After two cycles of therapy,
patients underwent follow-up CT scans of chest, ab-
domen, and pelvis as well as physical examination
for evaluation of response. Patients were treated every
three weeks until there was evidence of progression of
disease, increasing side effects or a maximum of one
year time period. Toxicity was graded using the NCI
Common Toxicity criteria.
Criteria for response
A complete response was defined as disappearance of
all clinical evidence of disease by physical examina-
tion and/or CT scan for 4 weeks. Partial response was
defined as 50% or greater reduction of tumor by phys-
ical examination and/or CT scan. Size of the tumor
was determined by multiplication of the two longest
perpendicular diameters. Patients with no change in
disease had stable disease for 4 weeks. Progressive
disease was defined as a 25% or greater increase of
tumor by physical examination and/or CT scan or
appearance of any new lesion.
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Statistical consideration
The primary objective of the study was to determine
the proportion of incurable esophageal cancer patients
who respond to docetaxel. The study was designed
as two stage trial with a decision to continue if the
response rate was 20% [10]. Enrollment would not
continue if the observed response rate was ≤ 5%. If 1
out of the first 10 patients responded, the second stage
would accrue to a total of 29 patients (80% power,
5% type 1 error). All eligible patients were included
in response, toxicity and survival analyses.
Results
Patient characteristics and response
From December 1997 to September 1999, 22 patients
were enrolled in the study. Patient characteristics are
listed in Table 1. The mean age of patients was 61
years and the majority of patients were white males.
Almost half of the patients had undergone an eso-
phagectomy and 27% of patients received prior radi-
ation therapy. Of the 22 patients, 11 was chemotherapy
naive and the remaining 11 had prior chemotherapy,
including 4 patients who had received prior paclit-
axel. Forty-one percent of patients received at least
2 cycles of chemotherapy. The maximum number of
cycles administered was eight. The liver and lungs
were predominant sites of metastatic disease.
Chemotherapy-naive patients achieved a response
rate of 18% (95% CI = 2.3 to 51.8) while patients
who received prior chemotherapy achieved a 0% re-
sponse rate (95% CI = 0 to 25). Overall, six patients
(27%) had stable disease. There were no complete
responses. The overall median survival time was 3.4
months (range 1–26 months) and the one-year survival
rate was 21%. Chemotherapy naive and prior pacl-
itaxel treated patients had a median survival time of
6 months. Patients treated with prior chemotherapy,
not including paclitaxel had a median survival time
of 4 months. The median time to progression was 1.4
months. To date, 2 of the 22 patients (11%) are alive
with a follow-up of 28 months. These two patients
were not the patients who achieved partial responses
to docetaxel chemotherapy.
During the trial, the accrual rate was less than ex-
pected at 12 patients per year. Due to poor accrual,
the trial was terminated prior to achieving the ori-
ginal sample size. In addition, to satisfy the originally
planned final decision rule, 2 out of the remaining 7
Table 1. Patient characteristics
Characteristics








Performance status 1 (0–2)








patients in the trial would have had to respond. As-
suming that the true response rate is 0.1, the chance of
this occurring is only 15%.
Toxicity
The grade 3 and 4 toxicities included neutropenia,
febrile neutropenia, fatigue, and anorexia (Table 2).
Fifteen (68%) patients experienced grade 3 and 4 neut-
ropenia. Of those patients, seven (32%) experienced
febrile neutropenia requiring inpatient hospitalization.
One (5%) patient experienced grade 3 peripheral
neuropathy and docetaxel therapy was subsequently
discontinued. This patient had received a total of eight
cycles of docetaxel. Three (14%) patients experienced
grade 3 and 4 fatigue and two (9%) patients experi-
enced anorexia. There was no grade 3 and 4 nausea,
vomiting, stomatitis, thrombocytopenia, or anemia.
Discussion
Previous single agent chemotherapy trials performed
mainly in patients with metastatic squamous cell car-
cinoma of the esophagus have reported low response
rates. Paclitaxel has been studied in both histologic
types of cancer of the esophagus with encouraging re-
ports of 28–34% response rates in chemotherapy naive
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Table 2. Toxicity of docetaxel chemotherapy
Toxicity Grade 3 Grade 4
N (%) N (%)
Neutropenia 4 (18%) 11 (50%)
Febrile neutropenia 7 (32%) –
Peripheral neuropathy 1 (5%) –
Fatigue 2 (9%) 1 (5%)
Anorexia 1 (5%) 1 (5%)
N = Number of patients
patients [8]. Docetaxel at 100 mg/m2 given intraven-
ously every 3 weeks has been studied in chemother-
apy naive patients with adenocarcinoma of the upper
gastrointestinal tract and the authors reported an over-
all 17% response rate [9]. The patients in that trial
primarily had gastric cancer, but 24% of the patients
had distal esophagus and gastro-esophageal junction
tumors. The objectives of this current trial were to
determine the complete and partial response rate of
docetaxel at 75 mg/m2 given intravenously every 3
weeks in patients with incurable adenocarcinoma of
the esophagus.
The overall response rate in this trial was only
9%, with no complete responses achieved. Although
the numbers were small in each group, the response
rate in chemotherapy naive patients was 18% while
patients with prior chemotherapy had a 0% response
rate. Twenty-seven percent of all patients had stable
disease. The 18% response rate in chemotherapy naive
patients was similar to that reported by Einzig et al.
[9].
The toxicities seen in this trial, regardless of the
patient’s prior chemotherapy status were acceptable.
The most significant toxicity was febrile neutropenia
(32%) followed by fatigue and anorexia. Docetaxel
administered at the higher dose of 100 mg/m2, 90%
grade 3 and 4 neutropenia as well as 46% of febrile
neutropenia were reported, necessitating future dose
reductions. As anticipated, docetaxel at 75 mg/m2 res-
ulted in fewer toxicities than when given at a higher
dose.
As a second line agent, docetaxel has been evalu-
ated in other tumor types including lung, ovarian and
breast cancer. In these trials, docetaxel generally has
shown activity in paclitaxel-resistant disease. Fossella
et al. treated patients with stage IIIB/IV non-small cell
lung cancer with docetaxel 100 mg/m2 or 75 mg/m2
intravenously every 3 weeks [11]. These lung cancer
patients with prior paclitaxel treatment were not strat-
ified at enrollment, but there were approximately 40%
of the patients previously treated with paclitaxel in the
study. Reportedly, prior paclitaxel treatment did not
affect the response or survival to docetaxel. Similarly,
Kavanagh et al. concluded that docetaxel administered
at 100 mg/m2 intravenously every 3 weeks was an
active second line treatment in patients with paclitaxel
refractory metastatic ovarian cancer [12]. In addition,
the same docetaxel dose was active in patients with
paclitaxel refractory metastatic breast cancer [13]. In
our study, patients who received prior taxane chemo-
therapy had an equivalent median survival time of 6
months compared to those who were chemotherapy
naive. Although the number of patients in this trial
was too few, this trend may support the hypothesis that
paclitaxel and docetaxel are non-cross resistant.
Promising preclinical and clinical data has sugges-
ted greater cytotoxic potency with docetaxel compared
to paclitaxel even as second line therapy. Unfortu-
nately, the limitiations of this trial does not allow for
any definitive conclusions to be made about the effic-
acy of single agent docetaxel in patients with incurable
adenocarcinoma of the esophagus.
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